ERBB2 and breast carcinoma: T-DXd is recommended for patients with unresectable or metastatic HER2-low breast cancer who have received one or two prior chemotherapies for metastatic disease (Strength of recommendation: 1; Strength of evidence: moderate, CQ34, systemic treatment part).